Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombiCoR-Vax: Sequential Immunochemotherapy in Refractory mCRC
NCT06522919Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell vaccine in metastatic colorectal cancer (mCRC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Jan 2025; status: recruiting.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06522919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522919.